Evolent Health amends credit agreement adding $250M in new debt facilities

Evolent Health, Inc.

Increased existing ABL revolver by $50M (with $25M funded); new delayed draw term loans of $125M and $75M.
Interest rates: ABL at SOFR + 4.00% or base + 3.00%; term loans at SOFR + 5.50% or base + 4.50%.
Maturity is earliest of 5 years from Dec 6, 2024, or 180 days before 2029 convertible notes maturity.
Borrowing under term loans requires total secured leverage ratio ≤ 2.00:1.00.
Upfront fees: 1% on ABL commitment; 2% (reducible to 1%) on term loan amounts funded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.